Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Ropinirole hydrochloride is a non-ergot dopamine agonist created based on the structure of dopamine, and exhibits antiparkinsonian effects by stimulating dopamine D 2 like receptors.”
“Consistent with its high lipophilicity, ropinirole exhibits a large volume of distribution (approximately 7 L/kg) and is cleared from the systemic circulation with an average elimination half-life of about 10 hours after transdermal administration.”
“It has been established from in vitro experiments that ropinirole is principally metabolised by the cytochrome P450 enzyme CYP1A2.”